Search

Your search keyword '"Nadaj-Pakleza A"' showing total 376 results

Search Constraints

Start Over You searched for: Author "Nadaj-Pakleza A" Remove constraint Author: "Nadaj-Pakleza A"
376 results on '"Nadaj-Pakleza A"'

Search Results

1. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP‑mediated disease reveals characteristic features useful for diagnosis

2. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis

4. Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study.

5. Defining the landscape of TIA1 and SQSTM1 digenic myopathy

6. The FLNC Ala1186Val Variant Linked to Cytoplasmic Body Myopathy and Cardiomyopathy Causes Protein Instability

7. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study

8. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

9. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

13. Dystrophies musculaires des ceintures associées aux mutations de TRIM32 : cohorte française et revue de la littérature

15. Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy

16. Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy

17. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

18. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

20. The FLNC Ala1186Val Variant Linked to Cytoplasmic Body Myopathy and Cardiomyopathy Causes Protein Instability

21. Biallelic RFC1-expansion in a French multicentric sporadic ataxia cohort

23. Long‐term prognosis of fatty‐acid oxidation disorders in adults: Optimism despite the limited effective therapies available

24. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

25. Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment

26. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

27. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

28. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.

29. Long‐term prognosis of fatty‐acid oxidation disorders in adults: Optimism despite the limited effective therapies available.

30. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study

31. Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple‐Source Capture–Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria

32. Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular Atrophy

33. Clinical and electrophysiological characteristics of women with X‐linked Charcot–Marie–Tooth disease

34. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

35. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

36. Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment

37. Hypertrophie musculaire : signe de bonne santé ou de maladie ?

38. Refining inflammatory myopathies incidence and characteristics: a quadruple source capture‐recapture survey using 2017 <scp>ACR</scp> / <scp>EULAR</scp> criteria

39. <scp> SORD </scp> ‐related peripheral neuropathy in a French and Swiss cohort: Clinical features, genetic analyses, and sorbitol dosages

40. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases

41. SORD‐related peripheral neuropathy in a French and Swiss cohort: clinical features, genetic analysis and sorbitol dosage.

45. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies

46. Characteristics of Patients With Late-Onset Pompe Disease in France.

47. Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy

48. A rise in cases of nitrous oxide abuse: neurological complications and biological findings

49. Genotype-phenotype correlations in valosin-containing protein disease

Catalog

Books, media, physical & digital resources